Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (211-220 of 466) with videos related to

Pageof 47
Sort By:
Cell Death & Disease|July 3, 2024
Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylationStefanie Enzenmüller, Alexandra Niedermayer, Felix Seyfried, et al.
Leukemia|August 29, 2019
Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN studyFrancesc Bosch, Guy Cantin, Agostino Cortelezzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow TransplantationKate Cwynarski, Anja van Biezen, Liesbeth de Wreede, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2022
Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and VenetoclaxMoritz Fürstenau, Jonathan Weiss, Adam Giza, et al.
Hemasphere|November 29, 2023
Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical StudiesSathej Gopalakrishnan, Rajeev Menon, Ahmed A Suleiman, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2020
Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potentialMoritz Bewarder, Gerhard Held, Lorenz Thurner, et al.
British Journal of Haematology|August 16, 2005
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II studyMark Ringhoffer, Norbert Blumstein, Bernd Neumaier, et al.
Genome Research|September 12, 2023
Nucleosome repositioning in chronic lymphocytic leukemiaKristan V Piroeva, Charlotte McDonald, Charalampos Xanthopoulos, et al.
Intensive Care Medicine Experimental|September 3, 2021
Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019Vadim Lesan, Moritz Bewarder, Carlos Metz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2007
Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factorsDirk Kienle, Tiemo Katzenberger, German Ott, et al.
Pageof 47

Showing results (211-220 of 466) with videos related to

Sort By:
Pageof 47
Cell Death & Disease|July 3, 2024
Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylationStefanie Enzenmüller, Alexandra Niedermayer, Felix Seyfried, et al.
Leukemia|August 29, 2019
Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN studyFrancesc Bosch, Guy Cantin, Agostino Cortelezzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow TransplantationKate Cwynarski, Anja van Biezen, Liesbeth de Wreede, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2022
Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and VenetoclaxMoritz Fürstenau, Jonathan Weiss, Adam Giza, et al.
Hemasphere|November 29, 2023
Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical StudiesSathej Gopalakrishnan, Rajeev Menon, Ahmed A Suleiman, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2020
Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potentialMoritz Bewarder, Gerhard Held, Lorenz Thurner, et al.
British Journal of Haematology|August 16, 2005
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II studyMark Ringhoffer, Norbert Blumstein, Bernd Neumaier, et al.
Genome Research|September 12, 2023
Nucleosome repositioning in chronic lymphocytic leukemiaKristan V Piroeva, Charlotte McDonald, Charalampos Xanthopoulos, et al.
Intensive Care Medicine Experimental|September 3, 2021
Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019Vadim Lesan, Moritz Bewarder, Carlos Metz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2007
Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factorsDirk Kienle, Tiemo Katzenberger, German Ott, et al.
Pageof 47